DrugCite
Search

VISUDYNE

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Visudyne Adverse Events Reported to the FDA Over Time

How are Visudyne adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Visudyne, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Visudyne is flagged as the suspect drug causing the adverse event.

Most Common Visudyne Adverse Events Reported to the FDA

What are the most common Visudyne adverse events reported to the FDA?

Visual Acuity Reduced
334 (8.04%)
Retinal Haemorrhage
216 (5.2%)
Disease Progression
115 (2.77%)
Choroidal Neovascularisation
97 (2.34%)
Condition Aggravated
75 (1.81%)
Detachment Of Retinal Pigment Epith...
72 (1.73%)
Vitreous Haemorrhage
61 (1.47%)
Retinal Detachment
60 (1.44%)
Retinal Oedema
58 (1.4%)
Retinal Pigment Epithelial Tear
56 (1.35%)
Back Pain
53 (1.28%)
Show More Show More
Retinal Degeneration
44 (1.06%)
Chorioretinal Disorder
42 (1.01%)
Macular Hole
42 (1.01%)
Infusion Related Reaction
40 (.96%)
Macular Degeneration
40 (.96%)
Metamorphopsia
39 (.94%)
Myocardial Infarction
38 (.92%)
Macular Oedema
36 (.87%)
Blindness
33 (.79%)
Subretinal Fibrosis
33 (.79%)
Blood Pressure Increased
29 (.7%)
Maculopathy
28 (.67%)
Eye Haemorrhage
27 (.65%)
Chest Pain
26 (.63%)
Retinal Ischaemia
26 (.63%)
Nausea
25 (.6%)
Pain
25 (.6%)
Post Procedural Complication
25 (.6%)
Polypoidal Choroidal Vasculopathy
24 (.58%)
Retinal Tear
24 (.58%)
Transient Ischaemic Attack
24 (.58%)
Disease Recurrence
23 (.55%)
Macular Scar
22 (.53%)
Off Label Use
22 (.53%)
Retinal Disorder
22 (.53%)
Scotoma
22 (.53%)
Retinal Scar
21 (.51%)
Dyspnoea
19 (.46%)
Retinal Exudates
19 (.46%)
Asthenia
18 (.43%)
Headache
18 (.43%)
Vision Blurred
18 (.43%)
Arthralgia
17 (.41%)
Fatigue
17 (.41%)
Hypoaesthesia
17 (.41%)
Intraocular Pressure Increased
17 (.41%)
Pain In Extremity
17 (.41%)
Blindness Unilateral
16 (.39%)
Cerebral Infarction
16 (.39%)
Loss Of Consciousness
16 (.39%)
Retinal Pigment Epitheliopathy
16 (.39%)
Cerebrovascular Accident
15 (.36%)
Drug Ineffective
15 (.36%)
Injection Site Extravasation
15 (.36%)
Choroidal Infarction
14 (.34%)
Dizziness
14 (.34%)
Fibrosis
14 (.34%)
Injection Site Pain
14 (.34%)
Angiogram Abnormal
13 (.31%)
Cataract
13 (.31%)
Cerebellar Infarction
13 (.31%)
Chorioretinal Atrophy
13 (.31%)
Choroidal Dystrophy
13 (.31%)
Incontinence
13 (.31%)
Retinal Cyst
13 (.31%)
Visual Field Defect
13 (.31%)
Asthma
12 (.29%)
Coma
12 (.29%)
Cough
12 (.29%)
Oedema Peripheral
12 (.29%)
Drug Hypersensitivity
11 (.26%)
Eye Disorder
11 (.26%)
Eye Pain
11 (.26%)
Glaucoma
11 (.26%)
Scar
11 (.26%)
Syncope
11 (.26%)
Vomiting
11 (.26%)
Convulsion
10 (.24%)
Fall
10 (.24%)
Paraesthesia
10 (.24%)
Anxiety
9 (.22%)
Chest Discomfort
9 (.22%)
Deafness
9 (.22%)
Extravasation
9 (.22%)
Haemorrhage
9 (.22%)
Hypoacusis
9 (.22%)
Hypoperfusion
9 (.22%)
Myalgia
9 (.22%)
Paralysis
9 (.22%)
Procedural Complication
9 (.22%)
Retinal Vascular Disorder
9 (.22%)
Viral Infection
9 (.22%)
Abdominal Pain Upper
8 (.19%)
Blood Creatinine Increased
8 (.19%)
Death
8 (.19%)
Hypertension
8 (.19%)
Hypotension
8 (.19%)
Influenza Like Illness
8 (.19%)
Infusion Site Erythema
8 (.19%)
Injection Site Erythema
8 (.19%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Visudyne, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Visudyne is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Visudyne

What are the most common Visudyne adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Visudyne, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Visudyne is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Visudyne According to Those Reporting Adverse Events

Why are people taking Visudyne, according to those reporting adverse events to the FDA?

Macular Degeneration
637
Choroidal Neovascularisation
176
Product Used For Unknown Indication
85
Polypoidal Choroidal Vasculopathy
64
Age-related Macular Degeneration
49
Drug Use For Unknown Indication
42
Show More Show More
Myopia
31
Retinal Neovascularisation
16
Retinal Vascular Disorder
13
Chorioretinopathy
10
Haemangioma Of Retina
9
Haemangioma
8
Retinal Disorder
4
Telangiectasia
4
Neovascularisation
4
Chorioretinal Disorder
4
Choroiditis
3
Chorioretinal Atrophy
3
Eye Disorder
3
Photodynamic Therapy
3
Macular Oedema
2
Choroid Neoplasm
2
Choroid Melanoma
2
Retinal Aneurysm
2
Eye Infection Toxoplasmal
2
Corneal Neovascularisation
2
Maculopathy
2
Toxoplasmosis
2
Prophylaxis Against Transplant Reje...
2
Histoplasmosis
2
Retinal Telangiectasia
2
Hamartoma
1
Retinal Exudates
1
Drug Exposure During Pregnancy
1
Ocular Vascular Disorder
1
Conjunctival Disorder
1
Presumed Ocular Histoplasmosis Synd...
1
Choroidal Dystrophy
1
Retinal Vein Occlusion
1
Eye Degenerative Disorder
1
Retinal Detachment
1
Anisometropia
1
Retinal Dystrophy
1
Retinal Ischaemia
1
Von Hippel-lindau Disease
1
Retinitis Histoplasma
1
Retinopathy
1

Drug Labels

LabelLabelerEffective
VisudyneQLT Ophthalmics, Inc.07-APR-10

Visudyne Case Reports

What Visudyne safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Visudyne. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Visudyne.